Why Bath & Body Works (BBWI) Is Down 9.8% After Cutting 2026 Outlook and Completing Buybacks
Bath & Body Works, Inc. BBWI | 0.00 |
- In early March 2026, Bath & Body Works reported that fourth-quarter sales slipped to US$2,724 million and net income to US$403 million, with full-year earnings per share from continuing operations easing to US$3.11 as it guided to lower 2026 sales and earnings.
- At the same time, the company completed a US$382.85 million buyback program, repurchasing 14,638,891 shares, while outlining plans to scale back promotional discounting and reposition the brand through product innovation and collections like the new Rooted line.
- Next, we’ll examine how Bath & Body Works’ reduced 2026 sales and earnings guidance could influence its longer-term investment narrative and outlook.
This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
Bath & Body Works Investment Narrative Recap
To stay invested in Bath & Body Works today, you need to believe the brand can convert its strong cash generation and loyal customer base into healthier, more stable earnings while it reins in discounting and refreshes its product lineup. The key near term catalyst is whether reduced promotions and new collections, like Rooted, can support sales without eroding traffic. The biggest risk is that softer 2026 sales and earnings guidance signals deeper pressure on margins and demand.
The most relevant recent update is the 2026 guidance cut, with management now expecting net sales to decline 4.5% to 2.5% and earnings per share of US$3.00 to US$3.25. This frames the current reset against earlier growth hopes and matters for anyone focused on catalysts such as digital expansion, new channels like Amazon, and brand innovation, because it highlights how much work is still needed to stabilize performance.
Yet beneath the new product buzz, investors should be aware of the risk that...
Bath & Body Works' narrative projects $8.1 billion revenue and $860.7 million earnings by 2028. This requires 3.1% yearly revenue growth and a $132.7 million earnings increase from $728.0 million today.
Uncover how Bath & Body Works' forecasts yield a $24.62 fair value, a 26% upside to its current price.
Exploring Other Perspectives
Before this guidance cut, the most optimistic analysts were baking in about US$8.3 billion of revenue and US$862 million of earnings by 2028, which is a far more upbeat view than the concerns around underperforming digital channels and mall exposure that now look more pressing.
Explore 8 other fair value estimates on Bath & Body Works - why the stock might be worth 13% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Bath & Body Works research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Bath & Body Works research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bath & Body Works' overall financial health at a glance.
Want Some Alternatives?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
